No­var­tis, Bay­er, Long­wood back ge­nomics start­up to speed search for im­munother­a­py tar­gets

Near­ly a cen­tu­ry passed be­tween the first pro­to-im­munother­a­py at­tempts in can­cer — crude and ob­scure but nonethe­less with some sci­en­tif­ic ba­sis — and Jim Al­li­son …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER